BDBM100806 US8507533, 114::US8507533, 115::US8507533, 330

SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O

InChI Key InChIKey=FNEBFXHBMCLZJO-UHFFFAOYSA-N

Data  2 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 100806   

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandPNGBDBM100806(US8507533, 115 | US8507533, 330 | US8507533, 114)
Affinity DataKi:  7.60nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
Go to US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandPNGBDBM100806(US8507533, 115 | US8507533, 330 | US8507533, 114)
Affinity DataKi:  15.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
Go to US Patent